Vor Biopharma Inc.
VOR
$0.634
$0.0142.26%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.96M | 6.70M | 7.21M | 8.00M | 7.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.31M | 28.51M | 29.04M | 32.33M | 28.12M |
| Operating Income | -31.31M | -28.51M | -29.04M | -32.33M | -28.12M |
| Income Before Tax | -30.71M | -27.56M | -27.84M | -30.80M | -26.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.71M | -27.56M | -27.84M | -30.80M | -26.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.71M | -27.56M | -27.84M | -30.80M | -26.26M |
| EBIT | -31.31M | -28.51M | -29.04M | -32.33M | -28.12M |
| EBITDA | -30.45M | -27.66M | -28.17M | -31.38M | -27.23M |
| EPS Basic | -0.44 | -0.40 | -0.41 | -0.45 | -0.39 |
| Normalized Basic EPS | -0.27 | -0.25 | -0.25 | -0.28 | -0.24 |
| EPS Diluted | -0.44 | -0.40 | -0.41 | -0.45 | -0.39 |
| Normalized Diluted EPS | -0.27 | -0.25 | -0.25 | -0.28 | -0.24 |
| Average Basic Shares Outstanding | 70.02M | 68.47M | 68.30M | 68.03M | 67.84M |
| Average Diluted Shares Outstanding | 70.02M | 68.47M | 68.30M | 68.03M | 67.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
